Eye drops could replace needles for wet AMD?

NCT ID NCT05637255

Completed Disease control Sponsor: Sylentis, S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and can improve or maintain vision. Participants used the drops for a set period, and their vision was measured after 42 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYL1801 eye drops
What this could lead to: If successful, SYL1801 could offer a non-invasive eye drop treatment for wet AMD, potentially reducing the need for frequent injections.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 99 participants. The eye drops may not improve vision as hoped, and long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACULAR DEGENERATION NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WET MACULAR DEGENERATION

Contacts and locations

Locations

SYL1801 Investigative Site

Brno, 62500, Czechia
SYL1801 Investigative Site

Chomutov, 43001, Czechia
SYL1801 Investigative Site

Frýdek-Místek, 738 01, Czechia
SYL1801 Investigative Site

Kyjov, 69701, Czechia
SYL1801 Investigative Site

Liberec, 46063, Czechia
SYL1801 Investigative Site

Ostrava, 70200, Czechia
SYL1801 Investigative Site

Prague, 14000, Czechia
SYL1801 Investigative Site

Prague, 17000, Czechia
SYL1801 Investigative Site

Gdansk, 80-809, Poland
SYL1801 Investigative Site

Krakow, 31-070, Poland
SYL1801 Investigative Site

Rzeszów, 35-017, Poland
SYL1801 Investigative Site

Warsaw, 01-258, Poland
SYL1801 Investigative Site

Bratislava, 85107, Slovakia
SYL1801 Investigative Site

Košice, 04011, Slovakia
SYL1801 Investigative Site

Poprad, 05801, Slovakia
SYL1801 Investigative Site

Žilina, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.